Viña, José
Escudero, Joaquín
Baquero, Miquel
Cebrián, Mónica
Carbonell-Asíns, Juan Antonio
Muñoz, José Enrique
Satorres, Encarnación
Meléndez, Juan Carlos
Ferrer-Rebolleda, José
Cózar-Santiago, Mª del Puig
Santabárbara-Gómez, Jose Manuel
Jové, Mariona
Pamplona, Reinald
Tarazona-Santabalbina, Francisco José
Borrás, Consuelo
Article History
Received: 25 May 2022
Accepted: 1 October 2022
First Online: 4 November 2022
Declarations
:
: The study was conducted across 2 sites in the city of Valencia, Spain, at the Department of Neurology of Hospital General and Hospital La Fe according to the protocol (see ExternalRef removed) and with the consensus ethics principles derived from international ethics guidelines, including the Declaration of Helsinki and the Council for International Organizations of Medical Sciences International Ethical Guidelines. The “Comité Ético de Investigación Clínica del Hospital Clínic Universitari de Valencia” approved the clinical study. Study participants provided written informed consent.The trial director, Professor José Viña, designed the trial, which was funded by a grant by the Spanish Government (SAF2016-75508-R from the Spanish Ministry of Economy and Competitivity). The authors vouch for the accuracy and completeness of the data, and the fidelity of the study to the protocol.
: We obtained permission from all the patients to publish their data.
: This was supported exclusively by public funds in Spain and was performed in two public hospitals in Valencia. No private industry support must be disclosed. Genistein-containing pills were bought from commercially available sources that were distributed in the chemist shop system in Spain. Moreover, no non-financial conflicts of interest exist for any of the authors.